Iovance Biotherapeutics (Iovance Biotherapeutics) Cash-to-Debt

: 3.69 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Iovance Biotherapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Iovance Biotherapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Iovance Biotherapeutics's Cash-to-Debt or its related term are showing as below:

IOVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.69 Med: 5013.35 Max: No Debt
Current: 3.69

During the past 13 years, Iovance Biotherapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 3.69. And the median was 5013.35.

IOVA's Cash-to-Debt is ranked worse than
59.09% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs IOVA: 3.69

Iovance Biotherapeutics Cash-to-Debt Historical Data

The historical data trend for Iovance Biotherapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

26.70

12.18

7.05

5.52

3.69

Iovance Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																5.52	7.53	3.11	4.55	3.69

Competitive Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Cash-to-Debt falls into.

Iovance Biotherapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Iovance Biotherapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	279.867	/	(7.777	+	68.085)
	=	3.69

Iovance Biotherapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	279.867	/	(7.777	+	68.085)
	=	3.69

Iovance Biotherapeutics (NAS:IOVA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Iovance Biotherapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

2LB:Germany 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Executives

Merrill A Mcpeak	director	PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wayne P. Rothbaum	director	C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Wendy L Yarno	director
Frederick G Vogt	officer: General Counsel	2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes	director	112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon	director
Ryan D Maynard	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky	officer: Chief Operating Officer	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin	officer: Chief Financial Officer	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg	officer: VP, Finance	C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf	officer: Chief Medical Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris	officer: Chief Financial Officer	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis	director, officer: President and CEO	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085